Clinical trials: Cancer, Carcinoma
Breast Cancer
Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)
The general objective of the study is to improve the care of women with Human Epidermal Growth Factor Receptor-2 (HER2) positive metastatic or locally advanced breast cancer by using a radio-labelled biomarker with whole body…
- Trial name
- PETRA (NCT01805908)
- Testing
- 111In-Pertuzumab + SPECT-CT
- Where
- 2 sites in Canada
- Volunteers
- 3 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Cancer
Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer
This study is designed to investigate the safety and efficacy of the combination of imatinib and vinorelbine in patients with advanced, anthracycline resistant breast cancer
- Trial name
- INV181 (NCT00372476)
- Testing
- Imatinib and Vinorelbine
- Where
- Germany
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Renal Cell
"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"
Retrospective study to collect data from Patients with advanced/metastatic renal cell carcinoma previously treated with Axitinib under standard clinical practice, to describe the clinical profile of the patients with a long…
- Trial name
- NCT03538717
- Where
- 40 sites in Spain
- Volunteers
- 157 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
ADOPT-lung is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery.
- Trial name
- ADOPT-lung (NCT06284317)
- Testing
- Adjuvant durvalumab
- Where
- 42 sites in Australia, Austria and 8 more
- Volunteers
- 290 people
- Sponsor
- ETOP IBCSG Partners Foundation
Metastatic Renal Cell Carcinoma, Metastatic Malignant Melanoma
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of AS1409 in single and repeated doses.
- Trial name
- NCT00625768
- Testing
- AS1409
- Where
- 4 sites in New Zealand, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Antisoma Research
Peritoneal Diseases
ERAS® Guidelines Validation of CRS With or Without HIPEC
Enhanced recovery after surgery (ERAS®) pathways have been shown to considerably reduce complications, length of stay and costs after most of surgical procedures by standardised application of best evidence-based perioperative…
- Trial name
- NCT05185791
- Testing
- Pre-ERAS® phase (current clinical practice), Post-ERAS® implementation phase
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 288 people
- Sponsor
- Hospices Civils de Lyon
Hepatocellular Carcinoma
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- TAQE (NCT05842174)
- Testing
- Hydroxychloroquine, Lipiodol
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- VA Office of Research and Development
Ductal Breast Carcinoma in Situ, Invasive Breast Cancer
Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.
An explanatory study comparing complementary treatment to breast conservative surgery with radiation therapy DCIS, T1-T2 N0 M0 (AJCC v8) 1 week schedule vs 3.1 weeks standard schedule, in order to determine the equivalence of…
- Conditions
- Ductal Breast Carcinoma in Situ, Invasive Breast Cancer, Early-stage Breast Cancer, Stage 0 Breast Cancer
- Trial name
- NCT05318274
- Testing
- Hypofractionated radiotherapy
- Where
- Mexico
- Volunteers
- 72 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Squamous Cell Carcinoma
Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate Nimotuzumab in different indications.
- Trial name
- NCT01232374
- Testing
- Nimotuzumab, cisplatin, Radiotherapy
- Where
- 17 sites in China
- Volunteers
- 144 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Cervical Cancer
Cervical Carcinoma in Shatby University Hospital and Its Relation to Human Papilloma Virus
incidence of detection of carcinogenic types of human papilloma virus in 60 cases of cervical cancer
- Trial name
- NCT05539274
- Testing
- human papilloma virus testing and genotyping in cervical cancer cases
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Hossam Hassan Aly Hassan El Sokkary
Bladder Urothelial Carcinoma, Bladder Cancer
Safety Analysis and Oncological Outcomes in HoLERT vs TURBT
Bladder urothelial cancer is the second most common urologic tumor and represents a worldwide public health problem. Most cases are diagnosed as non-muscle invasive tumors, and can be treated with transurethral resection of…
- Trial name
- NCT05833997
- Testing
- Monopolar Transurethral resection of bladder tumor, Holmium Laser resection of bladder tumor (HoLEBT)
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Bladder Cancer
Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
The goal of this clinical research study is to learn about the tolerability of nivolumab in patients who have bladder cancer, were previously treated with BCG immunotherapy, and who have a cystectomy (removal of all or part of…
- Trial name
- NCT03106610
- Testing
- Nivolumab, Questionnaires
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
HPV InfectioN, HPV-Related Carcinoma
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-45 Years
A total of 13500 Chinese women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 35-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1.
- Trial name
- NCT05262010
- Testing
- 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- Where
- 8 sites in China
- Volunteers
- 13,500 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Non-small Cell Lung Cancer
Prediction of Mediastinal Station IV Lymph Node Metastasis in Non-small Cell Lung Cancer
Mediastinal lymph node metastasis is a common metastasis pathway of non-small cell lung cancer (NSCLC), and its occurrence is closely related to the lymphatic drainage pattern, which is different in different pulmonary lobe…
- Trial name
- NCT06496360
- Testing
- Artificial Intelligence
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Qilu Hospital of Shandong University
Thyroid Carcinoma
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
This is a non-interventional, multi center post-authorization safety study that includes all patients diagnosed as Unresectable Differentiated Thyroid Carcinoma (DTC) and treated with Sorafenib within a certain period.
- Trial name
- JPMS-DTC (NCT02185560)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 453 people
- Sponsor
- Bayer
Lung Cancer, Nonsmall Cell, COPD
Breathe Easier II: A Dyad-based Multiple Behavior Intervention
This pilot randomized control trial (RCT) will test a 12-week, multiple behavior intervention physical activity and stress management for survivors with early stage lung cancer (stages I-III) and their family members (1 survivor…
- Conditions
- Lung Cancer, Nonsmall Cell, COPD, Self-Management, Physical Inactivity
- Trial name
- BE (NCT05956782)
- Testing
- Breathe Easier
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
Fallopian Tube Carcinoma, Ovarian Carcinoma
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
This phase II trial studies how well giving the insulin-like growth factor binding protein 2 [pUMVC3-hIGFBP-2 multi-epitope plasmid deoxyribonucleic acid (DNA) (IGFBP-2)] vaccine after one dose of carboplatin works to stop…
- Conditions
- Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT07495124
- Testing
- pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Washington
Non-small Cell Lung Cancer, Minimal Residual Disease
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation
To study the efficacy of sintilimab combined with anlotinib for perioperative non-small cell lung cancer. To explore the clearance effect of sintilimab combined with anlotinib for postoperative adjuvant therapy based on…
- Conditions
- Non-small Cell Lung Cancer, Minimal Residual Disease, Immunotherapy, Anti-angiogenesis
- Trial name
- NCT05460195
- Testing
- sintilimab combined with anlotinib, sintilimab monotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shanghai Chest Hospital
Neuroendocrine Carcinoma
Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)
To study the efficacy of everolimus combined with temozolomide as first-line treatment in advanced gastroenteropancreatic neuroendocrine carcinoma with a Ki67 of 20-55%, measured as disease control rate (non-progressive disease)…
- Trial name
- NCT02248012
- Testing
- Everolimus , temozolomide
- Where
- Norway
- Volunteers
- 38 people
- Sponsor
- Haukeland University Hospital
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma
- Trial name
- NCT00112619
- Testing
- topotecan hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pediatric Brain Tumor Consortium
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.